{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T13:10:00Z","timestamp":1724850600486},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T00:00:00Z","timestamp":1230681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12028-008-9170-z","type":"journal-article","created":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T20:00:20Z","timestamp":1231185620000},"page":"403-407","source":"Crossref","is-referenced-by-count":19,"title":["Safety of Imipenem\/Cilastatin in Neurocritical Care Patients"],"prefix":"10.1007","volume":"10","author":[{"given":"Jason","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Trimble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,31]]},"reference":[{"key":"9170_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/jac\/34.2.223","volume":"34","author":"FM MacKenzie","year":"1994","unstructured":"MacKenzie FM, Gould IM, Chapman DG, et al. Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother. 1994;34:223\u201330. doi: 10.1093\/jac\/34.2.223 .","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"9170_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/36.suppl_A.43","volume":"36","author":"M Hutchison","year":"1995","unstructured":"Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother. 1995;36(Suppl A):43\u201356.","journal-title":"J Antimicrob Chemother"},{"key":"9170_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/30.2.129","volume":"30","author":"M Hikada","year":"1992","unstructured":"Hikada M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-1 from porcine and human renal cortex. J Antimicrob Chemother. 1992;30:129\u201334. doi: 10.1093\/jac\/30.2.129 .","journal-title":"J Antimicrob Chemother"},{"key":"9170_CR4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/106002809302700418","volume":"27","author":"SL Pestotnik","year":"1993","unstructured":"Pestotnik SL, Classen DC, Evans RS, et al. Prospective surveillance of imipenem\/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother. 1993;27:497\u2013501.","journal-title":"Ann Pharmacother"},{"key":"9170_CR5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1046\/j.1528-1157.2001.34701.x","volume":"42","author":"BS Koppel","year":"2001","unstructured":"Koppel BS, Hauser WA, Politis C, et al. Seizures in the critically ill: the role of imipenem. Epilepsia. 2001;42:1590\u20133. doi: 10.1046\/j.1528-1157.2001.34701.x .","journal-title":"Epilepsia"},{"key":"9170_CR6","first-page":"377","volume":"18","author":"J Shimada","year":"1992","unstructured":"Shimada J, Hori S, Kanemitsu K, et al. A comparative study on the anticonvulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res. 1992;18:377\u201381.","journal-title":"Drugs Exp Clin Res"},{"key":"9170_CR7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7164\/antibiotics.48.408","volume":"48","author":"M Sunagawa","year":"1995","unstructured":"Sunagawa M, Matsumura H, Sumita Y, et al. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot. 1995;48:408\u201316.","journal-title":"J Antibiot"},{"key":"9170_CR8","unstructured":"Package Insert. Primaxin IV (imipenem and cilastatin for injection). Whitehouse Station, NJ: December 2007."},{"key":"9170_CR9","unstructured":"Package Insert. Merrem IV (meropenem for injection). Wilminton, DE: February 2007."},{"key":"9170_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006454-199102000-00009","volume":"10","author":"VK Wong","year":"1999","unstructured":"Wong VK, Wright HT, Ross LA, et al. Imipenem\/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1999;10:122\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"9170_CR11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00006454-198912000-00019","volume":"8","author":"F Aseni","year":"1989","unstructured":"Aseni F, Perez-Tamarit D, Otero MC, et al. Imipenem-cilastatin therapy in a child with meningitis caused by a multiply resistant Pneumococcus. Pediatr Infect Dis J. 1989;8:895. doi: 10.1097\/00006454-198912000-00019 .","journal-title":"Pediatr Infect Dis J"},{"key":"9170_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/1120009X.1993.11739221","volume":"5","author":"F Aseni","year":"1993","unstructured":"Aseni F, Otero MC, Perez-Tamarit D, et al. Risk\/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant Pneumococcus. J Chemother. 1993;5:133\u20134.","journal-title":"J Chemother"},{"key":"9170_CR13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00007611-198506000-00028","volume":"78","author":"K Rodriguez","year":"1985","unstructured":"Rodriguez K, Kickinson GM, Greenman RL. Successful treatment of gram-negative bacillary meningitis with imipenem\/cilastatin. South Med J. 1985;78:731\u20132. doi: 10.1097\/00007611-198506000-00028 .","journal-title":"South Med J"},{"key":"9170_CR14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1469-0691.2000.00082.x","volume":"6","author":"C Verwaest","year":"2000","unstructured":"Verwaest C. Meropenem versus imipenem\/cilastatin as empiric monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect. 2000;6:294\u2013302. doi: 10.1046\/j.1469-0691.2000.00082.x .","journal-title":"Clin Microbiol Infect"},{"key":"9170_CR15","first-page":"65","volume":"15","author":"U Hartenauer","year":"1997","unstructured":"Hartenauer U, Kljucar S, Bender HJ, et al. Meropenem versus imipenem\/cilastatin for the treatment of serious bacterial infections in the ICU. Antiinfective Drugs Chemother. 1997;15:65\u201370.","journal-title":"Antiinfective Drugs Chemother"},{"key":"9170_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/38.3.523","volume":"38","author":"F Colardyn","year":"1996","unstructured":"Colardyn F, Faulkner KL, Meropenem serious infection study group. Intravenous meropenem versus imipenem\/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother. 1996;38:523\u201337. doi: 10.1093\/jac\/38.3.523 .","journal-title":"J Antimicrob Chemother"},{"key":"9170_CR17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/BF01700407","volume":"16","author":"J Garau","year":"1997","unstructured":"Garau J, Blanquer J, Cobo L, et al. Prospective, randomized, multicentre study of meropenem versus imipenem as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis. 1997;16:789\u201396. doi: 10.1007\/BF01700407 .","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"9170_CR18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9343(88)90071-X","volume":"84","author":"G Calandra","year":"1988","unstructured":"Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem\/cilastatin. Am J Med. 1988;84:911\u20138. doi: 10.1016\/0002-9343(88)90071-X .","journal-title":"Am J Med"},{"key":"9170_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00365549950161808","volume":"31","author":"SR Norrby","year":"1999","unstructured":"Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis. 1999;31:3\u201310. doi: 10.1080\/00365549950161808 .","journal-title":"Scand J Infect Dis"},{"key":"9170_CR20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0924-8579(99)00040-0","volume":"11","author":"BA Cunha","year":"1999","unstructured":"Cunha BA. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents. 1999;11:167\u201377. doi: 10.1016\/S0924-8579(99)00040-0 .","journal-title":"Int J Antimicrob Agents"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-008-9170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12028-008-9170-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-008-9170-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:06:45Z","timestamp":1559441205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12028-008-9170-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,31]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9170"],"URL":"https:\/\/doi.org\/10.1007\/s12028-008-9170-z","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,31]]}}}